Percheron Therapeutics Ltd - Asset Resilience Ratio
Percheron Therapeutics Ltd (PER) has an Asset Resilience Ratio of 76.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Percheron Therapeutics Ltd (PER) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Percheron Therapeutics Ltd's Asset Resilience Ratio has changed over time. See PER equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Percheron Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PER company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$9.55 Million | 76.79% |
| Total Liquid Assets | AU$9.55 Million | 76.79% |
Asset Resilience Insights
- Very High Liquidity: Percheron Therapeutics Ltd maintains exceptional liquid asset reserves at 76.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Percheron Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Percheron Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Percheron Therapeutics Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Percheron Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 76.79% | AU$9.55 Million ≈ $6.76 Million |
AU$12.44 Million ≈ $8.80 Million |
-4.96pp |
| 2023-06-30 | 81.76% | AU$10.50 Million ≈ $7.43 Million |
AU$12.84 Million ≈ $9.09 Million |
-0.32pp |
| 2022-06-30 | 82.08% | AU$18.42 Million ≈ $13.03 Million |
AU$22.44 Million ≈ $15.88 Million |
-3.92pp |
| 2021-06-30 | 86.00% | AU$6.02 Million ≈ $4.26 Million |
AU$7.00 Million ≈ $4.95 Million |
+10.15pp |
| 2020-06-30 | 75.85% | AU$4.06 Million ≈ $2.87 Million |
AU$5.35 Million ≈ $3.79 Million |
-2.66pp |
| 2019-06-30 | 78.51% | AU$2.90 Million ≈ $2.05 Million |
AU$3.70 Million ≈ $2.62 Million |
-11.02pp |
| 2018-06-30 | 89.52% | AU$4.30 Million ≈ $3.04 Million |
AU$4.80 Million ≈ $3.40 Million |
+14.62pp |
| 2017-06-30 | 74.91% | AU$1.90 Million ≈ $1.35 Million |
AU$2.54 Million ≈ $1.80 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$5.33 Million ≈ $3.77 Million |
-- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more